Related Experiment Video
Updated: Feb 2, 2026

Multifunctional Hybrid Fe2O3-Au Nanoparticles for Efficient Plasmonic Heating
Published on: February 20, 2016
Multifunctional Nanoparticle Approach for Targeting Melanoma
Jun Li1, Jun Xie2, Jintao Zhu3
1Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
Malignant melanoma is the most aggressive and lethal form of skin cancer with an increasing incidence worldwide. In the past 5 years, the Food and Drug Administration has approved six targeted therapies or immunotherapies for the treatment of metastatic melanoma (Chapman et al., 2011; Falchook et al., 2012; Hauschild et al., 2012; Hodi et al., 2010; Ribas et al., 2015; Topalian et al., 2014). For the first time, interventions improve survival of this deadly disease. However, rapid resistance to BRAF/MEK inhibitors and lower rates of objective response or immune-related side effects for anti-CTLA-4 or anti-PD-1 monoclonal antibodies limited their widespread clinical applications.
Insights
New targeted therapies and immunotherapies have improved survival for metastatic melanoma patients. However, challenges like drug resistance and side effects limit their widespread clinical use.
Area of Science:
- Oncology
- Dermatology
- Immunology
Background:
- Malignant melanoma is an aggressive skin cancer with rising global incidence.
- Recent advances include six FDA-approved targeted therapies and immunotherapies for metastatic melanoma.
- These interventions represent the first to significantly improve survival rates for this deadly disease.
Purpose of the Study:
- To review the impact of recent therapeutic advancements in metastatic melanoma treatment.
- To highlight the efficacy and limitations of novel targeted therapies and immunotherapies.
- To discuss challenges hindering broader clinical application of these treatments.
Main Methods:
- Review of recent clinical trials and FDA approvals for melanoma treatments.
- Analysis of survival data and response rates for targeted therapies and immunotherapies.
- Evaluation of resistance mechanisms and immune-related adverse events associated with new treatments.
Main Results:
- Multiple targeted therapies (e.g., BRAF/MEK inhibitors) and immunotherapies (e.g., anti-CTLA-4, anti-PD-1) have demonstrated improved survival.
- Rapid development of resistance to BRAF/MEK inhibitors is a significant clinical challenge.
- Anti-CTLA-4 and anti-PD-1 therapies show limited objective response rates and can cause immune-related side effects.
Conclusions:
- Recent targeted therapies and immunotherapies offer unprecedented survival benefits for metastatic melanoma.
- Overcoming therapeutic resistance and managing side effects are critical for optimizing treatment outcomes.
- Further research is needed to enhance the efficacy and tolerability of melanoma treatments.
Related Concept Videos
Frustration and Conflict: Approach-Approach, Approach-Avoidance
One common type of conflict is the Approach–Approach Conflict. In this case, a person faces two desirable...
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Information Processing Approach
The Nativist Approach
Targeted Cancer Therapies
There are several types of targeted therapies against...
Kaplan-Meier Approach

